Rasmussen’s encephalopathy (RE): clinical features
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Rasmussen’s encephalopathy (RE): clinical features. This is a T-cell dominant inflammation. Fully referenced neurology checklist.
Pathology
- This is a T-cell dominant inflammation
- It may be triggered by a viral antigen
- Anti GluR3 antibodies are positive: these are possibly secondary to brain damage
Clinical stages
Locked: subscribe to see this section.
Demographic features
Locked: subscribe to see this section.
Risk factors
Locked: subscribe to see this section.
Clinical features
Locked: subscribe to see this section.
Associated ipsilateral features
Locked: subscribe to see this section.
Late-onset Rasmussen’s encephalopathy
Locked: subscribe to see this section.
Differentials: other hemispheric epileptic syndromes
Locked: subscribe to see this section.
References
- Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis. Brain 2005; 128:454-471.
- Varadkar S, Bien CG, Kruse CA, et al. Rasmussen's encephalitis: clinical features, pathophysiology, and treatment advances. Lancet Neurol 2014; 13:195-205.
- Granata T, Cross H, Theodore W, Avanzini G. Immune-mediated epilepsies. Epilepsia 2011; 52(suppl 3):5-11.
- Fauser S, Elger CE, Woermann F, Bien CG. Rasmussen encephalitis: Predisposing factors and their potential role in unilaterality. Epilepsia 2021 (Online ahead of print).
- Avberšek A, Miserocchi A, McEvoy AW, et al. Multiphasic presentation of Rasmussen's encephalitis. Epileptic Disord 2015; 17:315-320.
- And 5 more. Subscribe to see the full list
